Genzyme Corp. (Nasdaq: GENZ) has completed the transaction with Bayer HealthCare to acquire the worldwide rights to Campath®/MabCampath® (alemtuzumab), giving Genzyme primary responsibility for the development and commercialization of this promising multiple sclerosis (MS) therapeutic candidate. Genzyme is conducting two rapidly progressing phase 3 studies of alemtuzumab in relapsing-remitting MS patients.
Genzyme Completes Transaction with Bayer HealthCare
Posted by worldpharmanews 457 days ago (http://www.worldpharmanews.com)Who Voted for this Story
Comments